Search | Page 10 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Infections in myelodysplastic syndromes: a review

    ... use of DNA hypomethylating drugs (5-azacytidine and decitabine ) and lenalidomide in recent years for treating MDS has ... supportive care or low-dose cytarabine, those receiving decitabine had higher infection rates compared to those on supportive care. ...

    Research Review last updated 05/02/2016 - 9:28am.

  2. Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

    ... failed therapy with a hypomethylating agent (such as decitabine [Vidaza] and azacitidine [AZA]). ...

    Clinical Trial last updated 04/28/2016 - 12:21pm.

  3. Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE)

    ... agent (HMA), azacitidine (AZA) or decitabine (DEC). Status:  ...

    Clinical Trial last updated 04/27/2016 - 12:49pm.

  4. Sapacitibine shows promise for high-risk MDS patients

    ... are azacitidine (5-AZA, Vidaza®) and decitabine (Dacogen®). Both of these drugs are hypomethylating agents, ...

    Research Review last updated 05/02/2016 - 9:30am.

  5. Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation

    ... treated with Vidaza® ( azacitidine ), Dacogen® ( decitabine ), or both azacitidine and decitabine. The 76 patients in Cohort 2 underwent a stem cell transplant ...

    Research Review last updated 05/02/2016 - 9:26am.

  6. Amer Zeidan, M.D.

    ... to the existing drugs (such as azacitidine and decitabine ) and are not candidates for stem cell transplantation. Studies ...

    Bio last updated 03/11/2016 - 1:41pm.

  7. Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.

    ... or lymphoma chemotherapy or azacitidine or decitabine or tyrosine kinase inhibitor. Patients aged 18-70 years at ... at least one cycle of cytotoxic chemotherapy, azacitidine or decitabine. MDS patients must have < or = to 5% bone marrow ...

    Clinical Trial last updated 04/29/2016 - 3:51pm.

  8. Clofarabine in the treatment of myelodysplastic syndromes

    ... inhibitors, such as azacitidine and decitabine , are standard of care for patients with MDS who require ...

    Research Review last updated 05/02/2016 - 9:18am.

  9. Clinical Trials Report for April 2016

    ... agent (HMA), azacitidine (AZA) or decitabine (DEC). This study is being conducted in IL, MD, NY, ...

    Page last updated 08/10/2016 - 11:00am.

  10. Prognostic Relevance of the Kinetics of Worsening of Cytopenias in Lower-Risk MDS: A Substudy from the European Leukemianet Low Risk MDS (EUMDS) Registry

    ... (such as Vidaza® [ azacitidine ] or Dacogen® [ decitabine ]), a granulocyte colony-stimulating factor, hydroxyurea, ...

    Research Review last updated 05/02/2016 - 9:27am.